DGAP-News Caris Life Sciences (deutsch)

Caris Life Sciences Staffs for Aggressive European Growth

Caris Life Sciences

09.09.2010 15:30

---

Ian Abercrombie and Ian Walker Join the Rapidly Growing Biosciences Firm as
Vice Presidents to Accelerate Access to Breakthrough Molecular Cancer Testing
in Europe

IRVING, Texas, Sept. 9, 2010 (GLOBE NEWSWIRE) -- Recognizing the strong
commercial opportunities for its services in Europe, Caris Life Sciences?, a
leading biosciences company focused on driving precise and personalized
healthcare, today announced that it has named Ian Walker as its Vice President
of Strategic Marketing for Europe and Ian Abercrombie as its Vice President of
Commercial Operations for Europe. The new positions reflect the Company´s rapid
scaling for an aggressive growth strategy in the region.

The European commercialization strategy will focus on market strategies for
Caris´ flagship brands: the Caris Target Now(r) molecular profiling and
therapeutic guidance test, which provides treatment options associated with
clinical benefit for cancer patients, based on the molecular profile and
genetic disposition of the specific tumor; and the Carisome? Platform, a
proprietary blood-based technology currently being developed for earlier, more
accurate and less invasive testing for cancer and other complex diseases.

Ian Abercrombie joins Caris from Genzyme Therapeutics, where he most recently
served as the European Director of Oncology, with leadership responsibility for
commercial activities and performance for the company´s key hematology product
in EU, Eurasian and Australian affiliates. Previously, Abercrombie was the
Programme Director at Bioenvision, a U.K.-based start up, which was eventually
acquired by Genzyme. Abercrombie has also held commercial management positions
at Johnson & Johnson (Ortho-Biotech and Janssen Cilag divisions). He completed
a post-graduate certificate at Caledonian University in health education,
graduated from Stirling University with Bachelor of Arts in Marketing and
attended the Johnson & Johnson Management Development Program.

Ian Walker joins the company from his most recent position as Global Program
Director of Molecular Diagnostics for Novartis, where he helped to set up the
business unit and led the strategy, implementation and execution of the
company´s first molecular diagnostics program. Prior to that role, Walker
served both as the Respiratory Delivery Devices Director and Global Brand
Manager for respiratory pipeline products at Novartis. Walker has also held key
positions at AstraZeneca, including Brand Manager, Group Product Manager and UK
Brand Leader. Walker graduated from Imperial College with a Bachelor of
Sciences degree and ARCS in Chemistry.

´I am excited to have both these demonstrated leaders join our team, as they
will immediately contribute to Caris´ efforts to provide patients in Europe
innovative, cost-effective and highly-accurate testing services, ´ said Dominic
P. Moorhead, President European Operations. ´With the Carisome Platform and
Caris Target Now, Caris Life Sciences will deliver truly personalized medicine
to the European health systems, and these additions to our team will help build
the momentum.´

About Caris Life Sciences

Caris Life Sciences, a leading biosciences company, specializes in the
development and commercialization of the highest quality anatomic pathology,
molecular profiling, and blood-based diagnostic technologies, in the fields of
oncology, dermatopathology, hematopathology, gastrointestinal pathology and
urologic pathology. The company provides academic-caliber consultations for
thousands of patients a day, through its industry-leading team of expert,
subspecialty pathologists. Caris also offers advanced molecular analyses of
patient samples through prognostic testing services and genomic,
transcriptomic, and proteomic profiling to assist physicians in their treatment
of cancer. Currently, Caris is developing the Carisome(TM) platform, a
proprietary, blood-based technology for diagnosis, prognosis, and theranosis of
cancer and other complex diseases. The company is headquartered in the Dallas
metroplex, operates laboratories in the Dallas, Phoenix and Boston metro areas
and is entering the European markets through its first international location,
in Switzerland. For more information, visit www.carislifesciences.com.

CONTACT: Caris Life Sciences
Media Inquiries:
Holly Clark
214-596-7060
hclark@carisls.com

News Source: NASDAQ OMX

09.09.2010 15:30 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP´s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Caris Life Sciences

United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901136724
WKN:

End of Announcement DGAP News-Service

---

Bewerten Sie diesen Artikel: (

0

Bewertungen)